July 22, 2026 01:39 PM GMT Arrowhead Pharmaceuticals Inc | North America Topline Ph3 SHASTA 3/4 Results Positive Across the Board; Reiterate Overweight Rating Ph3 SHASTA-3/4 studies in SHTG met the primary endpoint (TG reduction; expected) and, most importantly, the key secondary endpoint (AP reduction; debated) with a well-tolerated safety profile. Though expectations were high, we expect results to drive meaningful upside, and we reiterate our OW rating. Key Takeaways | Stock Rating | | | Overweight | | | ...